Liver biochemistry findings in patients with COVID-19

August 28, 2020

Share article

The authors were interested in the liver chemistry profile of patients with COVID-19. They conducted a systematic review and meta-analysis in which they identified six studies of 586 patients with severe/critical illness compared with mild cases. The patients with severe/critical illness were more likely to have coronary artery disease (CAD), cerebrovascular disease and/or chronic obstructive pulmonary disease (COPD) than the mild cases. The authors identified a significant association between severe/critical COVID-19 and increased aspartate aminotransferase (AST, pooled mean difference [MD] 11.70 U/L, 95%CI 2.97–20.43), increased total bilirubin (pooled MD 0.14 mg/dL, 95%CI 0.06–0.22) and decreased albumin (pooled MD -0.68 g/L, 95%CI -0.81 to -0.55). More severe/critically ill cases were associated with leukocytosis, neutrophilia, lymphopenia, increased creatinine kinase, increased lactate dehydrogenase (LDH) and prolonged prothrombin time (PT). Therefore comorbidities are more prevalent in hospitalised patients with severe/critical COVID-19 and these patients are more likely to have abnormal liver chemistries.

Read more here

Kovalic AJ, Huang G, Thuluvath PJ & Satapathy SK ISSN: Hepatology; 10.1002/hep.31472


Added: August 28, 2020